Patents by Inventor Diane M. Otterness
Diane M. Otterness has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7537911Abstract: The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.Type: GrantFiled: April 17, 2007Date of Patent: May 26, 2009Assignees: Burnham Institute for Medical Research, Duke UniversityInventors: Robert T. Abraham, Diane M. Otterness
-
Publication number: 20080166713Abstract: The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.Type: ApplicationFiled: April 17, 2007Publication date: July 10, 2008Applicant: The Burnham InstituteInventors: Robert T. Abraham, Diane M. Otterness
-
Patent number: 7217551Abstract: The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.Type: GrantFiled: December 20, 2006Date of Patent: May 15, 2007Assignee: The Burnham InstituteInventors: Robert T. Abraham, Diane M. Otterness
-
Patent number: 7166716Abstract: The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.Type: GrantFiled: June 6, 2003Date of Patent: January 23, 2007Assignee: The Burnham InstituteInventors: Robert T. Abraham, Diane M. Otterness
-
Publication number: 20040248244Abstract: The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.Type: ApplicationFiled: June 6, 2003Publication date: December 9, 2004Inventors: Robert T. Abraham, Diane M. Otterness
-
Publication number: 20040235098Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described. Methods for determining a risk estimate for hormone dependent disease and methods for determining sulfonator status also are described.Type: ApplicationFiled: September 23, 2003Publication date: November 25, 2004Applicant: Mayo Foundation for Medical Education and Research, a Minnesota corporationInventors: Richard M. Weinshilboum, Rebecca B. Raftogianis, Thomas C. Wood, Diane M. Otterness
-
Publication number: 20030228675Abstract: The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.Type: ApplicationFiled: June 6, 2002Publication date: December 11, 2003Inventors: Robert T. Abraham, Diane M. Otterness
-
Publication number: 20020039775Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described. Methods for determining a risk estimate for hormone dependent disease and methods for determining sulfonator status also are described.Type: ApplicationFiled: April 10, 2001Publication date: April 4, 2002Applicant: Mayo Foundation for Medical Education and Research, Minnesota corporationInventors: Richard M. Weinshilboum, Rebecca B. Raftogianis, Thomas C. Wood, Diane M. Otterness
-
Patent number: 6265561Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described. Methods for determining a risk estimate for hormone dependent disease and methods for determining sulfonator status also are described.Type: GrantFiled: October 7, 1998Date of Patent: July 24, 2001Assignee: Mayo Foundation for Medical Education and ResearchInventors: Richard M. Weinshilboum, Rebecca B. Raftogianis, Thomas C. Wood, Diane M. Otterness
-
Patent number: 5470737Abstract: A recombinant DNA sequence is provided which encodes human thiopurine methyl transferase (TPMT), as well as a mammalian cell line having said recombinant DNA sequence incorporated into the genome thereof, so that the cells express high levels of human TPMT activity.Type: GrantFiled: October 3, 1994Date of Patent: November 28, 1995Assignee: Mayo Foundation for Medical Education and ResearchInventors: Richard M. Weinshilboum, Ronald Honchel, Ibrahim A. Aksoy, Carol L. Szumlanski, Thomas C. Wood, Diane M. Otterness, Eric D. Wieben